Related Experiment Videos
Historical perspective of defining Charcot-Marie-Tooth type 1B
1Veteran's Administration Puget Sound Health Care System, University of Washington Medical School, Seattle 98108, USA.
Insights
This study traces the genetic discovery of Charcot-Marie-Tooth disease type 1B (CMT1B). A mutation in the myelin P0 gene was identified, providing a molecular basis for this neurogenetic disorder.
Area of Science:
- Neurogenetics
- Clinical Genetics
Background:
- Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders affecting peripheral nerves.
- Early CMT research relied on clinical observations and linkage analysis before the widespread use of DNA markers.
Observation:
- A single family with CMT, initially diagnosed with peroneal muscular atrophy, was studied for 36 years.
- Genetic linkage studies in the 1980s mapped this CMT subtype to chromosome 1q, designated CMT1B.
Findings:
- A specific point mutation (Asp 90 Glu) in the myelin P0 gene was identified in the CMT1B family in 1993.
- This discovery provided the first molecular basis for CMT1B, linking a genetic defect to the disease phenotype.
Implications:
- The identification of the P0 gene mutation advanced the understanding of CMT1B pathogenesis.
- This case highlights the evolution of neurogenetic disorder diagnosis from clinical linkage studies to molecular genetics.
Abstract:
A single family (1521) with CMT has been followed for 36 years (1962-1998) at Children's Hospital and the University of Washington in Seattle. The family was initially called peroneal muscular atrophy with severely slowed motor nerve conduction velocities (5-15 m/sec). In the late 1970s the family was part of several genetic studies of CMT and in 1980 represented linkage of CMT to the Duffy (Fy) locus on chromosome 1q. This finding was confirmed in an Indiana CMT family by Stebbins and Conneally (1982). This subtype of CMT was designated 1B. These investigations represented some of the last successful linkage studies in the now seemingly "ancient" pre-DNA marker era. In 1993 Hayasaka and colleagues found a point mutation in the myelin P0 gene (Asp 90 Glu) in this family, giving CMT1B a molecular basis. The historical development of this "defining" of a neurogenetic disorder reveals interesting insights into the workings of clinical genetics over the past 3 decades.